Results
Belite Bio Inc.
03/02/2026 | Press release | Distributed by Public on 03/02/2026 05:09
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (Form 6-K)
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
| · | Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026 |
| · | Completed enrollment in the Phase 2/3 DRAGON II trial in STGD1 |
| · | Completed a $402 million underwritten public offering of American Depositary Shares |
| · | Conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET |
SAN DIEGO, March 2, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its preliminary, unaudited financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.
"2025 marked a defining year for Belite, highlighted by positive topline results from our pivotal Phase 3 DRAGON trial, establishing tinlarebant as a potential first-in-class therapy for Stargardt disease," said Dr. Tom Lin, Chairman and CEO of Belite Bio. "Combined with the completion of our $402 million public offering, we believe the Company is well positioned for the next phase of execution, and we remain on track to submit an NDA to the FDA in the second quarter of 2026 as we advance toward our goal of bringing the first approved treatment for Stargardt disease to people living with this debilitating disease."
Full Year 2025 Business Highlights and Upcoming Milestones
Clinical Highlights
Tinlarebant is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision.
Stargardt disease (STGD1): Accumulation of cytotoxic vitamin A byproducts (bisretinoids) compounds has been implicated in the onset and progression of STGD1, for which there is no approved treatment. Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1.
| · | DRAGON Trial: Completed, 24-month, 104 subjects, aged 12 to 20 years old, randomized (2:1, active: placebo), double-masked, placebo-controlled, global, multi-center, pivotal Phase 3 trial in adolescent STGD1 patients |
| o | Met its primary efficacy endpoint, demonstrating a statistically significant and clinically meaningful 35.7% reduction in the growth rate of macular lesions, measured as definitely decreased autofluorescence (DDAF) by fundus autofluorescence imaging, compared with placebo. |
| o | Achieved statistical significance when applying the pre-specified analysis (p-value = 0.0033). |
| o | Demonstrated in a post-hoc analysis that the treatment effect remained (35.4%) consistent with a p-value < 0.0001 when considering the progressive nature typically seen in STGD1. |
| o | On track to submit an NDA to the FDA in the second quarter of 2026. |
| · | DRAGON II Trial: Combination of a Phase 1b open-label trial to evaluate the pharmacokinetics and pharmacodynamics of tinlarebant in adolescent Japanese STGD1 patients and a Phase 2/3, 24-month, randomized (1:1, active: placebo), double-masked, placebo-controlled, multi-center trial in adolescent STGD1 patients aged 12 to 20 years old across Japan, the U.S., and the United Kingdom. |
| o | Targeted enrollment of 60 subjects was reached in January 2026. |
| o | Subjects who passed screening before enrollment cut off are allowed to be enrolled in the trial through early March. 72 subjects were enrolled as of February 27, 2026. |
| o | Trial design and inclusion of Japanese patients are intended to facilitate a future NDA in Japan. |
| o | Primary efficacy endpoint is the growth rate of atrophic lesions; safety and tolerability will also be assessed. |
Geographic Atrophy (GA): GA is a chronic degenerative disease of the retina that leads to blindness in the elderly. Accumulation of bisretinoids has been implicated in the progression of GA. There are currently no FDA-approved, orally administered treatments for GA.
| · | PHOENIX Trial: Ongoing, 24-month, randomized (2:1, active: placebo), double-masked, placebo-controlled, global, multi-center, pivotal Phase 3 trial in GA patients |
| o | Completed enrollment with 530 subjects. |
| o | Primary efficacy endpoint is the growth rate of atrophic lesions; safety and tolerability will also be assessed. |
| o | The Company expects to conduct an interim analysis. |
Corporate Highlights
| · | Completed a $402 million underwritten public offering of American Depositary Shares with overallotment fully exercised by the underwriters, with net proceeds intended to support commercialization preparation, development and expansion of pipelines, and general corporate purposes. |
Preliminary and Unaudited Fourth Quarter and Full Year 2025 Financial Results
Cash and Cash Equivalents: As of December 31, 2025, the Company had $352.9 million in cash and cash equivalents, compared with $31.7 million on December 31, 2024.
Investments: As of December 31, 2025, the Company had $419.7 million in U.S. treasury bills and U.S. treasury notes, compared to $113.5 million in liquidity funds, time deposits, and U.S. treasury bills as of December 31, 2024.
R&D Expenses:
For the three months ended December 31, 2025, research and development expenses were $14.6 million compared to $7.3 million for the same period in 2024. The increase in research and development expenses in the quarter was primarily attributable to (i) expenses related to the DRAGON II trial, (ii) lower Australian research and development tax incentive received and recognized as a reduction to research and development expenses in Q4 2025 as compared to Q4 2024; and (iii) Active Pharmaceutical Ingredient ("API") manufacturing expense. For the year ended December 31, 2025, research and development expenses were $45.4 million compared to $29.9 million for the same period in 2024. The increase was primarily attributable to (i) expenses related to the PHOENIX trial; (ii) share-based compensation expenses; and (iii) API manufacturing expenses, partially offset by the non-recurrence of a royalty payment recognized in 2024 for completion of a Phase 2 trial.
On a non-GAAP basis, excluding share-based compensation expenses, non-GAAP research and development expenses for the three months and year ended December 31, 2025, were $12.2 million and $36.2 million compared to $5.7 million and $26.2 million for the same periods in 2024, respectively.
Selling, G&A Expenses:
For the three months ended December 31, 2025, selling, general and administrative expenses were $13.5 million compared to $4.2 million for the same period in 2024. For the year ended December 31, 2025, selling, general and administration expenses were $38.8 million compared to $10.1 million for the same period in 2024. The increase in selling, general and administrative expenses in both the quarter and the full year was primarily due to increases in share-based compensation expenses and professional service fees.
On a non-GAAP basis, excluding share-based compensation expenses, non-GAAP selling, general and administrative expenses for the three months ended December 31, 2025, were $4.2 million compared to $1.5 million for the same period in 2024. For the full year 2025, non-GAAP selling, general and administrative expenses were $9.1 million compared to $4.8 million for the full year 2024.
Other Income:
For the three months ended December 31, 2025, other income was $2.8 million compared to $1.4 million for the same period in 2024. For the year ended December 31, 2025, other income was $6.6 million compared to $3.9 million for the same period in 2024. The increase in both the quarter and full year was primarily due to interest income from bank deposits, time deposits and U.S. treasury bills.
Net Loss:
For the three months ended December 31, 2025, the Company reported a GAAP net loss of $25.3 million, compared to a GAAP net loss of $10.1 million for the same period in 2024. For the year ended December 31, 2025, the Company reported a GAAP net loss of $77.6 million, compared to a GAAP net loss of $36.1 million for the same period in 2024.
On a non-GAAP basis, excluding share-based compensation expenses, the Company reported a non-GAAP net loss of $13.6 million for the three months ended December 31, 2025, compared to a non-GAAP net loss $5.9 million for the same period in 2024. For the year ended December 31, 2025, the non-GAAP net loss was $38.7 million, compared to a non-GAAP net loss of $27.2 million for the same period in 2024.
Webcast Information
Belite Bio will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit https://events.q4inc.com/attendee/547616305. A replay will be available for approximately 90 days following the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.
Belite Bio Inc. published this content on March 02, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 02, 2026 at 11:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]